List of Excipients in Branded Drug BUPIVACAINE HCI AND EPINEPHRINE

Generic Drugs Containing BUPIVACAINE HCI AND EPINEPHRINE

Company	Ingredient	NDC	Excipient
HF Acquisition Co LLC DBA HealthFirst	bupivacaine hci and epinephrine	51662-1399	CITRIC ACID MONOHYDRATE
HF Acquisition Co LLC DBA HealthFirst	bupivacaine hci and epinephrine	51662-1399	HYDROCHLORIC ACID
HF Acquisition Co LLC DBA HealthFirst	bupivacaine hci and epinephrine	51662-1399	METHYLPARABEN

What are the Most Frequently-Used Excipients in BUPIVACAINE HCI AND EPINEPHRINE?

# Of NDCs	Excipient
1	CITRIC ACID MONOHYDRATE
1	HYDROCHLORIC ACID
1	METHYLPARABEN

# Bupivacaine HCl and Epinephrine Excipient Strategy and Commercial Opportunities

Last updated: September 25, 2026

Bupivacaine hydrochloride with epinephrine is a mature injectable local anesthetic combination with low active-ingredient patent risk and meaningful opportunities in formulation quality, preservative control, packaging, supply reliability, and differentiated delivery. The principal commercial targets are sterile generic injection, preservative-free presentations, dental and office-based procedure formats, and products designed to reduce administration errors.

What is bupivacaine HCl with epinephrine?

Bupivacaine HCl with epinephrine is a sterile injectable local anesthetic used for local or regional anesthesia. Epinephrine is added to reduce local vascular absorption, prolong anesthetic effect, and provide a visual or physiologic indicator of inadvertent intravascular administration.

Typical marketed strengths include:

Product attribute	Common configuration
Bupivacaine HCl concentration	0.25% or 0.5%, equivalent to 2.5 or 5 mg/mL
Epinephrine concentration	1:200,000, approximately 5 micrograms/mL
Route	Local infiltration, peripheral nerve block, caudal or epidural administration, depending on labeling
Dosage form	Sterile aqueous injection
Container	Single-dose vial, ampule, cartridge, or ready-to-use syringe
Preservative status	Preservative-free and multidose formats may differ
pH	Acidic to mildly acidic, adjusted for stability and solubility
Primary commercial comparators	Marcaine with epinephrine, Sensorcaine with epinephrine, and generic bupivacaine HCl/epinephrine injections

FDA-approved labeling limits use by concentration, route, patient population, and maximum dose. Product-specific labeling must control formulation, preservative, container, and administration claims (FDA, 2023a; DailyMed, 2024a).

What excipients are used in bupivacaine HCl and epinephrine injection?

The core excipient system is relatively simple. The main formulation functions are solubilization, isotonicity, pH control, metal-ion control, and protection against oxidation.

Excipient or component	Typical function	Commercial relevance
Water for Injection	Vehicle	Must meet sterile injectable quality requirements
Sodium chloride	Tonicity adjustment	Supports physiologic osmolality and injection comfort
Hydrochloric acid or sodium hydroxide	pH adjustment	Controls bupivacaine solubility and product stability
Sodium metabisulfite or related sulfite	Antioxidant in epinephrine-containing products	Can reduce epinephrine oxidation but creates sulfite-sensitivity labeling considerations
Methylparaben or another antimicrobial preservative	Multidose microbial protection	Generally unsuitable for neuraxial use when preservative-free presentation is required
Nitrogen or controlled headspace	Oxygen reduction	Can limit epinephrine oxidation in selected container systems
Chelating agent, where justified	Trace-metal control	May support epinephrine stability but can affect regulatory comparability

The most important technical issue is the interaction between epinephrine oxidation and the product's pH, oxygen exposure, light exposure, trace metals, container closure, and antioxidant system. Bupivacaine itself is comparatively stable in aqueous solution, while epinephrine is more sensitive to oxidation and discoloration.

An excipient strategy should therefore be built around epinephrine stability rather than bupivacaine solubility alone.

Which excipient strategy is most commercially attractive?

The strongest strategy is usually a preservative-free, single-dose, ready-to-use injection with a simple excipient profile and robust epinephrine stability.

Preservative-free formulation

A preservative-free product is commercially attractive for epidural, peripheral nerve block, obstetric, surgical, and hospital use. It reduces concerns about preservative exposure and broadens compatibility with procedures in which preservative-free local anesthetic is preferred.

The principal design requirements are:

• Single-dose container configuration
• Low extractables and leachables
• Reliable stopper reseal or sealed-unit integrity
• Adequate protection from light and oxygen
• No antimicrobial preservative
• Stability through labeled shelf life and expected temperature excursions

This format has a higher packaging cost than a multidose vial but can command better institutional acceptance and reduce the risk of preservative-related procurement exclusions.

Multidose formulation

A multidose vial can reduce unit cost and support office-based or dental use. Its commercial value depends on the target market. It requires antimicrobial preservation and a validated multidose-use period. A formulation designed for neuraxial use may not be appropriate for a multidose presentation.

The key risk is market segmentation. A lower-cost multidose product cannot replace a preservative-free product in every hospital or procedure setting.

Sulfite-controlled formulation

Epinephrine-containing local anesthetic products commonly use a sulfite antioxidant system. Sulfite sensitivity is a labeling and procurement consideration. A sulfite-reduced or sulfite-free product could offer differentiation, but it would require a strong stability package demonstrating acceptable epinephrine potency, impurity control, color stability, and shelf life.

This is a technically attractive but higher-risk opportunity. The absence of sulfite alone may not support a premium unless the product addresses a defined clinical or institutional purchasing requirement.

Ready-to-use syringe or cartridge

A prefilled syringe can reduce preparation steps and medication-selection errors. Dental cartridges can support high-volume procedure markets, but they require specialized glass, elastomer, crimping, dimensional, and compatibility controls.

The main commercial advantages are:

• Lower preparation burden
• Reduced vial access
• Lower dosing and labeling error risk
• Potential support for ambulatory surgery and office procedures
• Better workflow integration

The main disadvantages are higher packaging costs, device regulatory complexity, and greater dependence on component supply.

What FDA regulatory pathway applies to bupivacaine HCl and epinephrine?

Bupivacaine HCl with epinephrine is a small-molecule injectable drug. A U.S. generic product would generally use an abbreviated new drug application if it can demonstrate pharmaceutical equivalence, bioequivalence where applicable, and compliance with applicable quality and sterility requirements.

The regulatory focus is not limited to the active ingredients. FDA will evaluate:

• Strength and concentration
• Dosage form and route
• Preservative status
• Inactive ingredients
• Container closure system
• Sterility and particulate matter
• Endotoxin control
• Stability
• Extractables and leachables
• Labeling and warnings
• In-use stability for multidose products
• Compatibility of the product with the proposed presentation

For a parenteral generic, differences in excipients may be acceptable when supported by safety, quality, and product-performance data. A formulation change that affects preservative status, administration route, or labeled use can create a more complex regulatory program (FDA, 2019; FDA, 2023b).

What is the Orange Book status of bupivacaine HCl and epinephrine?

The core bupivacaine and epinephrine molecules are long-established active ingredients. Their original composition-of-matter patent protection has expired. Commercial competition is therefore driven primarily by abbreviated applications, manufacturing capability, customer contracts, and product availability.

Orange Book analysis should distinguish among:

1. The active ingredient combination.
2. Specific injectable strengths.
3. Preservative-free presentations.
4. Formulation or manufacturing patents, if listed.
5. Method-of-use patents, if listed.
6. Pediatric or other regulatory exclusivity.
7. Device or packaging rights that may not appear as drug patents.

For this mature combination, the principal generic-entry question is usually whether an applicant can meet injectable-product requirements rather than whether a basic molecule patent remains enforceable.

A current Orange Book review should be performed for the exact reference-listed drug, strength, route, and dosage form because listing status can vary by product and may change after regulatory updates (FDA, 2024a).

When does bupivacaine HCl and epinephrine lose exclusivity?

The active-ingredient exclusivity period has already expired. Bupivacaine was first developed and commercialized decades ago, and epinephrine is an older established drug substance. The combination is therefore commercially open to generic competition, subject to FDA approval and any product-specific listed patent or regulatory issue.

The relevant timeline is:

Exclusivity element	Status
Bupivacaine composition-of-matter protection	Expired
Epinephrine composition-of-matter protection	Expired
Original combination protection	Expired or no longer commercially controlling
New formulation patents	Possible, but product-specific
Method-of-use patents	Possible, but must be reviewed against the exact product
Regulatory exclusivity	Not expected to block ordinary generic competition for this mature product
Biosimilar exclusivity	Not applicable

Liposomal bupivacaine products, including extended-release formulations, should not be treated as interchangeable with conventional bupivacaine HCl and epinephrine. Their formulation, administration profile, labeling, and potential patent estate are different.

Are Paragraph IV challenges relevant to this product?

Paragraph IV litigation is possible but is not the central risk for the conventional combination. A generic applicant may make a Paragraph IV certification if a listed patent is asserted against the reference product. For an old immediate-release injectable combination, the more likely outcome is a Paragraph III certification, a certification that no relevant patent is listed, or a non-infringement and invalidity position directed at a product-specific formulation or presentation patent.

Potential Paragraph IV targets could include:

• Preservative-free injectable formulations
• Specific antioxidant systems
• Stabilized epinephrine combinations
• Premixed syringes
• Cartridge systems
• Extended stability or packaging configurations
• Narrow method-of-use claims

The practical value of a Paragraph IV strategy depends on whether the patent claims cover the proposed formulation rather than the historical active ingredients. A generic product with different excipients, container closure, and manufacturing conditions may avoid some formulation claims, while a close formulation copy may create greater infringement exposure.

What patent litigation affects bupivacaine HCl and epinephrine?

No broad, active patent barrier is expected to prevent ordinary competition in conventional bupivacaine HCl with epinephrine injection. Litigation exposure is more likely to arise from adjacent products, particularly long-acting or liposomal bupivacaine formulations, than from the conventional solution.

The relevant legal distinctions are:

Issue	Risk assessment
Core bupivacaine molecule	Low patent risk
Core epinephrine molecule	Low patent risk
Conventional aqueous combination	Low to moderate, depending on listed patents
Preservative-free presentation	Moderate formulation and packaging risk
Prefilled syringe or cartridge	Moderate device and container risk
Liposomal bupivacaine	Separate and potentially stronger patent environment
Manufacturing process	Possible process patent or trade-secret risk
Method of use	Product-specific; claim scope must be reviewed

Settlement agreements are not a predictable barrier in a market with multiple established generic suppliers. Any commercial launch assessment should review current ANDA litigation records, FDA patent listings, and district court docket activity for the exact reference product.

What manufacturing and intellectual-property barriers exist?

The active ingredients are not the main barriers. The barriers are operational and quality-related.

Epinephrine stability

Epinephrine degradation can produce potency loss, discoloration, and impurity growth. The development program should evaluate:

• Oxygen exposure
• Headspace composition
• Light exposure
• Trace-metal contamination
• pH drift
• Antioxidant concentration
• Container closure permeability
• Freeze-thaw and temperature excursion effects

Sterile manufacturing

A sterile injectable product requires validated aseptic processing or terminal sterilization where compatible. Critical manufacturing controls include:

• Bioburden
• Bacterial endotoxins
• Visible and subvisible particles
• Filter compatibility
• Fill-volume accuracy
• Container closure integrity
• Media fills
• Cleaning validation
• Hold-time studies

Container closure

Amber glass may reduce light exposure, but packaging selection must also account for adsorption, delamination, elastomer compatibility, sulfite interaction, and extractables. Plastic systems can improve handling but may create oxygen-permeation or leachable concerns.

Supply chain

Commercial resilience depends on access to qualified sources of:

• Bupivacaine HCl
• Epinephrine
• Sterile glass or polymer containers
• Elastomer closures
• Antioxidant excipients
• Injectable-grade sodium chloride
• Secondary packaging with light protection

A dual-source strategy is particularly valuable because sterile injectable shortages can generate temporary pricing power and hospital demand.

What commercial opportunities exist?

The most practical opportunities are incremental rather than molecule-based.

Opportunity	Target buyer	Value proposition	Development burden
Preservative-free vial	Hospitals, surgery centers	Broad procedural compatibility	Moderate
Ready-to-use syringe	Ambulatory surgery, emergency care	Workflow and error reduction	Moderate to high
Dental cartridge	Dental practices	Convenient dosing and handling	Moderate
Multidose vial	Offices and clinics	Lower unit cost	Moderate
Sulfite-reduced formulation	Selected institutions and patients	Differentiated excipient profile	High
Dual-strength portfolio	Hospitals and distributors	Procurement simplification	Low to moderate
Contract-manufactured private label	Distributors and group purchasing organizations	Supply continuity	Moderate
Shortage-resilient product	Hospitals	Availability and allocation protection	Moderate
Specialty regional packaging	International distributors	Local presentation compliance	Moderate

The best near-term business case is usually a reliable generic portfolio with 0.25% and 0.5% strengths, preservative-free positioning, competitive packaging, and dependable supply. A premium formulation requires a clear purchasing advantage, not only a reformulated excipient list.

How does bupivacaine HCl with epinephrine compare with liposomal bupivacaine?

Attribute	Conventional bupivacaine HCl with epinephrine	Liposomal bupivacaine
Dosage form	Aqueous solution	Extended-release multivesicular formulation
Main commercial position	Low-cost local anesthetic	Longer-duration postoperative analgesia
Generic competition	High	More limited and patent-sensitive
Excipient complexity	Low to moderate	High
Stability challenge	Epinephrine oxidation and sterile injectable stability	Particle structure, release profile, and complex formulation stability
Typical price pressure	High	Lower price competition, depending on market
Key IP risk	Product-specific formulation or packaging	Formulation, manufacturing, and method-of-use patents
Biosimilar pathway	Not applicable	Not applicable

A conventional bupivacaine HCl/epinephrine product should not be marketed as equivalent to a liposomal bupivacaine product for duration of action or clinical performance unless FDA labeling supports the claim.

What geographic coverage and licensing opportunities exist?

The United States is a mature generic market with substantial hospital purchasing pressure. Commercial opportunities may be stronger in markets where local anesthetic supply is concentrated among a small number of suppliers or where preservative-free injectable products are imported.

Licensing opportunities include:

• Regional marketing rights for an approved injectable
• Contract manufacturing for hospital suppliers
• Private-label supply for distributors
• Technology licensing for ready-to-use packaging
• Co-development of sulfite-controlled or oxygen-managed formulations
• Dual sourcing arrangements with hospital systems

A licensee should distinguish drug approval rights from manufacturing rights. A supplier with an approved drug product but no dependable sterile fill capacity may have limited commercial value during shortage conditions.

How strong is the patent estate for bupivacaine HCl and epinephrine?

The patent estate is weak for the conventional active ingredients and potentially stronger only around differentiated presentations.

Patent category	Relative strength
Bupivacaine composition patent	Expired
Epinephrine composition patent	Expired
Conventional combination	Low
Basic aqueous injectable formulation	Low
Preservative-free formulation	Moderate if claims are narrow and technically supported
Antioxidant or oxygen-control system	Moderate
Prefilled syringe or cartridge	Moderate
Liposomal bupivacaine	Potentially stronger and separate
Manufacturing process	Fact-specific
Trade secrets and know-how	Commercially important despite limited patent scope

Trade secrets covering oxygen control, fill-finish parameters, container selection, and stability optimization may have more practical value than broad patent claims in this market.

What generic launch scenarios exist?

Three launch scenarios are commercially plausible.

Price-led launch

The applicant supplies standard vials at a discount to established generic products. Success depends on cost of goods, sterile capacity, wholesaler access, and hospital contracting. This is the fastest route but has limited differentiation.

Availability-led launch

The applicant positions the product around reliable supply, dual manufacturing sites, and shortage response. Hospitals may accept a modest premium for continuity when conventional suppliers face allocations.

Workflow-led launch

The applicant uses a ready-to-use syringe, cartridge, or unit-dose packaging format. The product competes on labor savings, medication safety, and procedure efficiency rather than active-ingredient price.

Revenue exposure is highest in hospital and ambulatory surgery contracts, where a single product can support recurring institutional demand. Dental and office-based markets offer broader customer reach but greater channel fragmentation.

Key Takeaways

• Bupivacaine HCl with epinephrine is a mature small-molecule injectable with expired core active-ingredient protection.
• Conventional generic competition is primarily constrained by sterile manufacturing, epinephrine stability, packaging, and supply reliability.
• Preservative-free single-dose products offer the broadest hospital and procedural positioning.
• Multidose products can reduce cost but may have narrower clinical and institutional acceptance.
• Sulfite reduction is technically differentiated but requires substantial stability and labeling support.
• Prefilled syringes and cartridges create commercial value through workflow and dosing convenience.
• Biosimilar risk does not apply because this is a small-molecule drug.
• Paragraph IV and formulation-patent risk should be assessed against the exact reference product and presentation.
• The strongest near-term opportunity is a reliable 0.25% and 0.5% preservative-free generic portfolio with robust packaging and dual-source supply.
• Liposomal bupivacaine is a separate product category and should not be used as a direct patent or commercial comparator without a product-specific analysis.

FAQs

Is epinephrine an active pharmaceutical ingredient or an excipient in this product?

Epinephrine is an active ingredient because it contributes a pharmacologic effect. It is not an excipient, even though it also modifies local absorption and duration.

Can a bupivacaine HCl product omit epinephrine and remain therapeutically equivalent?

No. A bupivacaine-only injection is a different product from bupivacaine HCl with epinephrine. The formulations have different active ingredients, labeling, stability requirements, and clinical uses.

Is sodium metabisulfite necessary in every bupivacaine and epinephrine injection?

No. Its use depends on the formulation and stability data. An alternative antioxidant or oxygen-control strategy may be possible, but the product must demonstrate acceptable epinephrine potency and impurity control.

Are preservatives acceptable in epidural bupivacaine products?

Preservative-free formulations are generally preferred when the product is labeled for epidural or neuraxial administration. The approved product label determines the permitted route and preservative status.

Does a patent on liposomal bupivacaine block a conventional bupivacaine HCl injection?

Not automatically. Patent infringement depends on the asserted claim language and the composition, process, or use of the accused product. Conventional aqueous bupivacaine HCl with epinephrine is technically distinct from liposomal bupivacaine.

References

1. DailyMed. (2024a). Bupivacaine hydrochloride and epinephrine injection: Product labeling. U.S. National Library of Medicine.

2. U.S. Food and Drug Administration. (2019). ANDAs for certain highly purified synthetic peptides: Guidance for industry. U.S. Department of Health and Human Services.

3. U.S. Food and Drug Administration. (2023a). Marcaine and Marcaine with epinephrine prescribing information. U.S. Department of Health and Human Services.

4. U.S. Food and Drug Administration. (2023b). Injectable suspensions and emulsions: Guidance for industry. U.S. Department of Health and Human Services.

5. U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations, 44th ed. U.S. Department of Health and Human Services.

6. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary, General Chapters <1>, <71>, <85>, <788>, and <1207>. USP.